Involvement of vasopressin v1- and v2-receptors in histamine-and stress-induced secretion of ACTH and β-endorphin
Research output: Contribution to journal › Journal article › Research › peer-review
Arginine-vasopressin (AVP) seems to be involved in the histamine (HA)- and stress-induced release of ACTH and β-endorphin (β-END). We studied the effect of selective AVP V1- or V2-receptor blockade on the ACTH and β-END response to HA or restraint stress in conscious male rats. HA (270 nmol) administered intracerebroventricularly or 5 min of restraint stress caused a 3-to 7-fold increase in the plasma levels of ACTH and β-END immunoreactivity (β-ENDir). Pretreatment of the animals with the nonselective V1+2-receptor antagonist [l-Pmp-2-Z)-Phe-4-Ile-8-Arg]vasopressin, which was administered intravenously in a low (23 nmol) or a high dose (90 nmol) inhibited the HA-or restraint stress-induced secretion of ACTH and β-ENDir 60 and 25-70%, respectively. Pretreatment with equipotent doses of the selective V1-receptor antagonist [l-(p-tBu)Pmp-2-Tyr(0-Me)-8-D-Arg]vasopressin (25 nmol) and/or the selective V2-receptor antagonist [l-Pmp-2-D-IIe-4-Ile-8-Arg]vasopres-sin (7.0 nmol) attenuated the response of ACTH and β-ENDir to HA or restraint stress by 60-80 and 40-60%, respectively. In general, these doses of antagonists had no effect on basal hormone levels. We conclude that AVP takes part in the mediation of HA- and restraint stress-induced ACTH and β-END secretion. This effect seems to be mediated via both AVP V1 and V2-receptors or a less selective receptor with ligand specificity for both V1- and V2-receptor antagonists.
Original language | English |
---|---|
Journal | Neuroendocrinology |
Volume | 57 |
Issue number | 3 |
Pages (from-to) | 503-509 |
Number of pages | 7 |
ISSN | 0028-3835 |
DOIs | |
Publication status | Published - 1993 |
- ACTH, Histamine, Pro-opiomelanocortin, Stress, Vasopressin, Vasopressin antagonists, Vasopressin receptors, β-Endorphin
Research areas
ID: 283516844